Israeli biopharmaceutical company Omnix Medical has raised $25 million in a Series C funding round, marking a significant milestone in the fight against antibiotic-resistant infections.
This funding, announced on October 15, 2025, was co-led by Harel Insurance & Finance and the European Innovation Council (EIC) Fund, with participation from existing investors like Entrée Capital and new investors such as Prevail Partners.
Addressing a Global Health Crisis with Innovative Solutions
The rise of drug-resistant bacteria poses a severe threat to global health, often rendering conventional antibiotics ineffective.
Omnix Medical, founded in 2015, is at the forefront of developing next-generation anti-infectives, focusing on life-threatening infections caused by Gram-negative bacteria like Acinetobacter baumannii.
The company’s lead compound, OMN6, is a novel antimicrobial peptide therapy designed to combat bacterial strains resistant to last-line treatments such as carbapenems and colistin.
Impact of the Funding on Future Developments
This $25 million investment will enable Omnix to complete Phase II proof-of-concept trials for OMN6, a critical step toward bringing this therapy to market.
Since its inception, Omnix has raised a total of $43 million, reflecting strong investor confidence in its mission to tackle one of the most pressing challenges in modern medicine.
Historically, the company has received support from initiatives like the €10.8 million grant from the EU in 2021, underscoring its role in addressing antibiotic resistance on a global scale.
Looking Ahead: A Future Without Antibiotic Resistance?
Looking to the future, successful trials of OMN6 could pave the way for a new class of antimicrobials, offering hope to millions affected by hospital-acquired infections annually.
The broader impact of Omnix’s work could reshape treatment protocols in healthcare settings, reducing mortality rates associated with resistant pathogens.
As antibiotic resistance continues to escalate, innovations from companies like Omnix Medical are crucial for safeguarding public health, potentially influencing policy and research worldwide.
Alfred Lee
